News

Latest Summary Corporate Presentation

May 2025

View Presentation

02 Apr 2025	Daily Telegraph	Dementia disaster warning
26 Mar 2025	The Australian	Top of mind: ASX companies tackling neurological disorders
05 Mar 2025	HotCopper	Executive Interview HotCopper with Dr Steven Gourlay: Xanamem: Alzheimer’s breakthrough set for 2025, 2026
27 Feb 2025	The Australian	The furore over how to treat Alzheimer’s just got a lot more complicated
12 Feb 2025	PR Newswire	Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
05 Feb 2025	PR Newswire	Actinogen announces new and unique nonproprietary name of ’emestedastat’ for Xanamem
05 Feb 2025	ABC Radio	Audio Recording: ABC Radio Melbourne interview with Dr Steven Gourlay (3m 28s)
05 Feb 2025	Hobart Mercury	Drug Win for Aussie firm
05 Feb 2025	10 First News	Executive Interview: 10 First News with Dr Steven Gourlay
06 Jan 2025	Daily Mail Online	Hopes new drug likened to ‘exercise in a pill’ will deal a major blow against Alzheimer’s
09 Dec 2024	PR Newswire	Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
16 Nov 2024	7 News Australia	New magic pill to help treat Alzheimer’s disease
16 Nov 2024	Sky News Australia	New breakthrough pill being trialled to combat Alzheimer’s
16 Nov 2024	10 News Australia	Xanamem: The potential ‘Holy Grail’ for the treatment of Alzheimers
16 Nov 2024	Courier Mail	Alzheimer’s Hope: Disease breakthrough could be ‘Holy Grail’
16 Nov 2024	Daily Telegraph	New pill promises hope for millions: ‘Holy Grail’ for Alzheimer’s
16 Nov 2024	Herald Sun	Pill may deliver hope for millions: ‘Holy Grail’ for Alzheimer’s
26 Aug 2024	PR Newswire	Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
12 Aug 2024	PR Newswire	Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
26 Jun 2024	PR Newswire	Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
22 Apr 2024	PR Newswire	Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024	PR Newswire	First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024	PR Newswire	Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
28 Nov 2023	PR Newswire	Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
13 Oct 2023	PR Newswire	Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
26 Sep 2023	PR Newswire	Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
07 Jun 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023	Media	Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
30 Mar 2023	PR Newswire	Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
01 Mar 2023	Biotech Daily	Actinogen Appoints Nicki Vasquez Non-Executive Director
01 Feb 2023	Biotech Daily	Actinogen Appoints Dr Dana Hilt CMO